• 1
    Samuelsson B (2012) Role of basic science in the development of new medicines: examples from the eicosanoid field. J Biol Chem 287:1007010080.
  • 2
    Hannemann F, Bichet A, Ewen KM, Bernhardt R (2007) Cytochrome P450 systems—biological variations of electron transport chains. Biochim Biophys Acta 1770:330344.
  • 3
    Bernhardt R (2006) Cytochromes P450 as versatile biocatalysts. J Biotechnol 124:128145.
  • 4
    Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, Steenbergen C, Zeldin DC, Goldstein J (2007) Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35:682688.
  • 5
    Westphal C, Konkel A, Schunck WH (2011) CYP-eicosanoids—a new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat 96:99108.
  • 6
    Wang H, Jiang Y, Liu Y, Lin C, Cheng G, Chen X, Hao B, Tan W, Lin D, He F (2006) CYP2J2*7 single nucleotide polymorphism in a Chinese population. Clin Chim Acta 365:125128.
  • 7
    Xiao B, Li X, Yan J, Yu X, Yang G, Xiao X, Voltz JW, Zeldin DC, Wang DW (2010) Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther 334:784794.
  • 8
    Imig JD (2012) Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 92:101130.
  • 9
    Imig JD, Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8:794805.
  • 10
    Zhang Y, El-Sikhry H, Chaudhary KR, Batchu SN, Shayeganpour A, Jukar TO, Bradbury JA, Graves JP, DeGraff LM, Myers P, Rouse DC, Foley J, Nyska A, Zeldin DC, Seubert JM (2009) Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 297:H37–H46.
  • 11
    Herse F, Lamarca B, Hubel CA, Kaartokallio T, Lokki AI, Ekholm E, Laivuori H, Gauster M, Huppertz B, Sugulle M, Ryan MJ, Novotny S, Brewer J, Park JK, Kacik M, Hoyer J, Verlohren S, Wallukat G, Rothe M, Luft FC, Muller DN, Schunck WH, Staff AC, Dechend R (2012) Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. Circulation 126:29902999.
  • 12
    Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnes CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio JA, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW, Zeldin DC (2012) Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 122:178191.
  • 13
    Panigrahy D, Greene ER, Pozzi A, Wang DW, Zeldin DC (2011) EET signaling in cancer. Cancer Metastasis Rev 30:525540.
  • 14
    Panigrahy D, Kaipainen A, Greene ER, Huang S (2010) Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev 29:723735.
  • 15
    Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC, Wang DW (2005) Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65:47074715.
  • 16
    Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S, Zhou J, Xiao X, Zhang XA, Edin ML, Card JW, Wang J, Zeldin DC, Wang DW (2007) Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res 67:66656674.
  • 17
    Lee CA, Jones JP III, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA (2012) Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos 40:943951.
  • 18
    Chen C, Li G, Liao W, Wu J, Liu L, Ma D, Zhou J, Elbekai RH, Edin ML, Zeldin DC, Wang DW (2009) Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther 329:908918.
  • 19
    Matsumoto S, Hirama T, Matsubara T, Nagata K, Yamazoe Y (2002) Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 30:12401245.
  • 20
    Skorupa E, Kemper B (1998) Signals for retention of cytochrome P450 in the endoplasmic reticulum. Methods Mol Biol 107:251266.
  • 21
    Cosme J, Johnson EF (2002) Analyzing binding of N-terminal truncated, microsomal cytochrome P450s to membranes. Methods Enzymol 357:116120.
  • 22
    Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE (2000) Microsomal cytochrome P450 2C5: comparison to microbial P450s and unique features. J Inorg Biochem 81:183190.
  • 23
    Hsu PY, Wang LH (2003) Protein engineering of thromboxane synthase: conversion of membrane-bound to soluble form. Arch Biochem Biophys 416:3846.
  • 24
    Cosme J, Johnson EF (2000) Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem 275:25452553.
  • 25
    von Wachenfeldt C, Richardson TH, Cosme J, Johnson EF (1997) Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. Arch Biochem Biophys 339:107114.
  • 26
    Kim HJ, Lee SB, Guengerich FP, Park YI, Dong MS (2007) Effects of N-terminal modification of recombinant human cytochrome P450 1A2 on catalytic activity. Xenobiotica 37:356365.
  • 27
    Ahn T, Guengerich FP, Yun CH (1998) Membrane insertion of cytochrome P450 1A2 promoted by anionic phospholipids. Biochemistry 37:1286012866.
  • 28
    Davydov DR (2011) Microsomal monooxygenase as a multienzyme system: the role of P450-P450 interactions. Expert Opin Drug Metab Toxicol 7:543558.
  • 29
    Subramanian M, Tam H, Zheng H, Tracy TS (2010) CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab Dispos 38:10031009.
  • 30
    Pernecky SJ, Larson JR, Philpot RM, Coon MJ (1993) Expression of truncated forms of liver microsomal P450 cytochromes 2B4 and 2E1 in Escherichia coli: influence of NH2-terminal region on localization in cytosol and membranes. Proc Natl Acad Sci USA 90:26512655.
  • 31
    Berka K, Hendrychová T, Anzenbacher P, Otyepka M (2011) Membrane position of ibuprofen agrees with suggested access path entrance to cytochrome P450 2C9 active site. J Phys Chem A 115:1124811255.
  • 32
    Conner KP, Woods CM, Atkins WM. (2011) Interactions of cytochrome P450s with their ligands. Arch Biochem Biophys 50:5665.
  • 33
    Denisov IG, Sligar SG (2011) Cytochromes P450 in nanodiscs. Biochim Biophys Acta 1814:223229.
  • 34
    Bayburt TH, Sligar SG (2010) Membrane protein assembly into Nanodiscs. FEBS Lett 584:17211727.
  • 35
    Ritchie TK, Grinkova YV, Bayburt TH, Denisov IG, Zolnerciks JK, Atkins WM, Sligar SG (2009) Chapter 11—Reconstitution of membrane proteins in phospholipid bilayer nanodiscs. Methods Enzymol 464:211231.
  • 36
    Leitz AJ, Bayburt TH, Barnakov AN, Springer BA, Sligar SG (2006) Functional reconstitution of Beta2-adrenergic receptors utilizing self-assembling Nanodisc technology. Biotechniques 40:601612.
  • 37
    Boldog T, Grimme S, Li M, Sligar SG, Hazelbauer GL (2006) Nanodiscs separate chemoreceptor oligomeric states and reveal their signaling properties. Proc Natl Acad Sci USA 103:1150911514.
  • 38
    Nath A, Atkins WM, Sligar SG (2007) Applications of phospholipid bilayer nanodiscs in the study of membranes and membrane proteins. Biochemistry 46:20592069.
  • 39
    Das A, Grinkova YV, Sligar SG (2007) Redox potential control by drug binding to cytochrome P450 3A4. J Am Chem Soc 129:1377813779.
  • 40
    Das A, Sligar SG (2009) Modulation of the cytochrome P450 reductase redox potential by the phospholipid bilayer. Biochemistry 48:1210412112.
  • 41
    Tark SH, Das A, Sligar S, Dravid VP (2010) Nanomechanical detection of cholera toxin using microcantilevers functionalized with ganglioside nanodiscs. Nanotechnology 21:435502.
  • 42
    Marty MT, Das A, Sligar SG (2012) Ultra-thin layer MALDI mass spectrometry of membrane proteins in nanodiscs. Anal Bioanal Chem 402:721729.
  • 43
    Das A, Zhao J, Schatz GC, Sligar SG, Van Duyne RP (2009) Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy. Anal Chem 81:37543759.
  • 44
    Zhao J, Das A, Zhang X, Schatz GC, Sligar SG, Van Duyne RP (2006) Resonance surface plasmon spectroscopy: low molecular weight substrate binding to cytochrome p450. J Am Chem Soc 128:1100411005.
  • 45
    Kim DH, Kim KH, Isin EM, Guengerich FP, Chae HZ, Ahn T, Yun CH (2008) Heterologous expression and characterization of wild-type human cytochrome P450 1A2 without conventional N-terminal modification in Escherichia coli. Protein Expr Purif 57:188200.
  • 46
    Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ, Johnson EF (1995) Universal approach to the expression of human and rabbit cytochrome P450s of the 2c subfamily in Escherichia coli. Arch Biochem Biophys 323:8796.
  • 47
    Looman AC, Bodlaender J, Comstock LJ, Eaton D, Jhurani P, Deboer HA, Vanknippenberg PH (1987) Influence of the codon following the aug initiation codon on the expression of a modified Lacz gene in Escherichia coli. EMBO J 6:24892492.
  • 48
    Barnes HJ, Arlotto MP, Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA 88:55975601.
  • 49
    Stormo GD, Schneider TD, Gold LM (1982) Characterization of translational initiation sites in E. coli. Nucleic Acids Res 10:29712996.
  • 50
    Schauder B, McCarthy JE (1989) The role of bases upstream of the Shine-Dalgarno region and in the coding sequence in the control of gene expression in Escherichia coli: translation and stability of mRNAs in vivo. Gene 78:5972.
  • 51
    Yamasaki T, Izumi S, Ide H, Ohyama Y (2004) Identification of a novel rat microsomal vitamin D3 25-hydroxylase. J Biol Chem 279:2284822856.
  • 52
    DeVore NM, Scott E (2012) Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 482:116119.
  • 53
    Fisher CW, Caudle DL, Martin-Wixtrom C, Quattrochi LC, Tukey RH, Waterman MR, Estabrook R (1992) High-level expression of functional human cytochrome P450 1A2 in Escherichia coli. FASEB J 6:759764.
  • 54
    Messina A, Nencioni S, Gervasi PG, Gotlinger KH, Schwartzman ML, Longo V (2010) Molecular cloning and enzymatic characterization of sheep CYP2J. Xenobiotica 40:109118.
  • 55
    Xu Z, Sigler P (1998) GroEL/GroES: structure and function of a two-stroke folding machine. J Struct Biol 124:129141.
  • 56
    Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:23792385.
  • 57
    Sligar SG (1976) Coupling of spin, substrate, and redox equilibria in cytochrome P450. Biochemistry 15:53995406.
  • 58
    Denisov IG, Baas BJ, Grinkova YV, Sligar SG (2007) Cooperativity in cytochrome P450 3A4: linkages in substrate binding, spin state, uncoupling, and product formation. J Biol Chem 282:70667076.
  • 59
    Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, Zeldin DC (1997) Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272:1255112559.
  • 60
    Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF (2008) Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283:1722717237.
  • 61
    Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF (2004) Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279:94979503.
  • 62
    Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, Funae Y (2002) Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298304.
  • 63
    Kelley LA, Sternberg M (2009) Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 4:363371.
  • 64
    Lomize MA, Lomize AL, Pogozheva ID, Mosberg H (2006) OPM: orientations of proteins in membranes database. Bioinformatics 22:623625.
  • 65
    Kang W, Liu KH, Ryu JY, Shin J (2004) Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 813:7580.
  • 66
    Liu KH, Kim MG, Lee DJ, Yoon YJ, Kim MJ, Shon JH, Choi CS, Choi YK, Desta Z, Shin JG (2006) Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos 34:17931797.
  • 67
    Denisov IG, Makris TM, Sligar SG, Schlichting I (2005) Structure and chemistry of cytochrome P450. Chem Rev 105:22532277.
  • 68
    Sulistyaningdyah WT, Ogawa J, Li QS, Maeda C, Yano Y, Schmid RD, Shimizu S (2005) Hydroxylation activity of P450 BM-3 mutant F87V towards aromatic compounds and its application to the synthesis of hydroquinone derivatives from phenolic compounds. Appl Microbiol Biotechnol 67:556562.
  • 69
    Isin EM, Guengerich FP (2008) Substrate binding to cytochromes P450. Anal Bioanal Chem 392:10191030.
  • 70
    Fisher MT, Sligar SG (1985) Control of heme protein redox potential and reduction rate—linear free-energy relation between potential and ferric spin state equilibrium. J Am Chem Soc 107:50185019.
  • 71
    Bridges A, Gruenke L, Chang YT, Vakser IA, Loew G, Waskell L (1998) Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase. J Biol Chem 273:1703617049.
  • 72
    Shen S, Strobel HW (1993) Role of lysine and arginine residues of cytochrome P450 in the interaction between cytochrome P4502B1 and NADPH-cytochrome P450 reductase. Arch Biochem Biophys 304:257265.
  • 73
    Shimizu T, Tateishi T, Hatano M, Fujii-Kuriyama Y (1991) Probing the role of lysines and arginines in the catalytic function of cytochrome P450d by site-directed mutagenesis. Interaction with NADPH-cytochrome P450 reductase. J Biol Chem 266:33723375.
  • 74
    Poulos TL (1996) Approaches to crystallizing P450s. Methods Enzymol 272:358368.
  • 75
    Poulos TL (1995) Cytochrome P450. Curr Opin Struct Biol 5:767774.
  • 76
    Aiba I, Yamasaki T, Shinki T, Izumi S, Yamamoto K, Yamada S, Terato H, Ide H, Ohyama Y (2006) Characterization of rat and human CYP2J enzymes as vitamin D 25-hydroxylases. Steroids 71:849856.
  • 77
    Kagawa N, Cao Q (2001) Osmotic stress induced by carbohydrates enhances expression of foreign proteins in Escherichia coli. Arch Biochem Biophys 393:290296.
  • 78
    Joseph RE, Andreotti AH (2008) Bacterial expression and purification of interleukin-2 tyrosine kinase: single step separation of the chaperonin impurity. Protein Expr Purif 60:194197.
  • 79
    Causey KM, Eyer CS, Backes WL (1990) Dual role of phospholipid in the reconstitution of cytochrome P-450 LM2-dependent activities. Mol Pharmacol 38:134142.
  • 80
    Kapust RB, Tözsér J, Fox JD, Anderson DE, Cherry S, Copeland TD, Waugh D (2001) Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng 14:9931000.